Understanding the Genetic Roots of Cholesterol

For some people, high cholesterol isn’t just about food or exercise—it’s in their DNA. Genes can play a significant role in determining cholesterol levels, meaning that even with a healthy lifestyle, some individuals are still at risk. One key player in this is the ANGPTL3 gene, which influences how the body processes fats, such as LDL cholesterol (commonly called “bad” cholesterol) and triglycerides. If this gene is overactive, it can make fat breakdown harder, leading to higher blood cholesterol levels.

What’s more, cholesterol issues don’t impact everyone equally. Marginalized communities often face higher rates of heart disease, partly due to unequal access to healthcare and treatments. Add in the genetic factor, and the challenge becomes even greater.

This is why understanding the genetic side of cholesterol is so important. It helps us see beyond oversimplified solutions like just “eating better” or exercising more. For some, the problem goes deeper, and tackling it requires more advanced tools—tools that can address the root cause at the genetic level.

Introducing CRISPR-Cas9 Gene Editing

Imagine having the power to edit the blueprint of life—your DNA—to address health issues at their core. That’s exactly what CRISPR-Cas9 gene editing does. It’s like having molecular scissors that can cut and modify specific parts of your genetic code, opening the door to treating diseases previously thought untreatable.

When it comes to cholesterol, CRISPR is a game-changer. Scientists have discovered that by targeting and “switching off” certain genes in the liver, like the ANGPTL3 gene, which increases LDL cholesterol and triglycerides, CRISPR can reduce these harmful blood fats significantly. For individuals with genetic lipid disorders, this means addressing the root of the problem instead of just managing symptoms with daily medications.

CRISPR doesn’t just stop at treating cholesterol—it rewrites the story altogether. Think about it: instead of worrying about taking pills for years, people could receive a one-time infusion that alters their DNA to fix the issue directly. This is more than just innovation—it’s a step toward solving chronic health problems in a simple, potentially life-changing way.

What makes this technology so fascinating is its precision. Unlike older therapies that might affect unrelated parts of your body, CRISPR works on exactly what it’s supposed to—nothing more, nothing less. This level of accuracy minimizes risks and boosts its promise as a transformative tool in medicine. And while it’s still early days, the possibilities are immense, especially for conditions linked to our genetic makeup.

CTX310: A Potential Cholesterol Game-Changer

CTX310 is paving the way for a whole new approach to tackling cholesterol. Using the groundbreaking CRISPR-Cas9 technology, this experimental treatment targets high cholesterol and triglycerides at their genetic source. It focuses on the ANGPTL3 gene, which plays a key role in controlling how the body breaks down fats. By “switching off” this gene in the liver, CTX310 has shown remarkable results in early trials. A single infusion led to LDL cholesterol levels dropping by nearly 50% and triglycerides by about 55%—results far beyond what researchers had initially hoped for. one-time infusion leading to a reduction of LDL cholesterol by nearly 50% and triglycerides by about 55%.

What sets CTX310 apart is its ability to deliver big reductions in both types of harmful fats at the same time. CTX310 is the first therapy to achieve large reductions in both LDL cholesterol and triglycerides simultaneously. This is a big deal for people dealing with mixed lipid disorders—conditions where both LDL cholesterol and triglycerides are elevated, increasing the risk of heart attacks and strokes.

For those who’ve struggled with traditional treatments, CTX310’s potential to simplify care is groundbreaking. It represents a move toward a future where managing cholesterol doesn’t have to mean years of medication but could instead be addressed with a single treatment designed to last.

Cholesterol Justice: A Health Equity Perspective

High cholesterol isn’t just a health issue—it’s tied to inequality. Communities facing systemic barriers, such as limited access to health care, healthy food, and education, are hit hardest by conditions like heart disease and stroke. These challenges are even more significant when you consider genetics, where some individuals are predisposed to high cholesterol levels regardless of lifestyle. In the U.S., about 35% of adults have total cholesterol levels of 200 mg/dL or higher, and nearly 26.4% of U.S. adults have elevated LDL cholesterol.

The costs of managing these conditions are another barrier. Many treatments require daily pills or regular injections—solutions that aren’t always affordable or accessible. This is where a permanent cholesterol solution like CTX310 could make a major difference. By targeting cholesterol and triglycerides directly at the genetic level, it offers the potential for lasting results in a single treatment. For marginalized groups, this could reduce reliance on expensive medications and remove the stress of ongoing care, creating opportunities for better health outcomes.

Cholesterol disparities aren’t just about biology—they’re about fairness. Innovations like CTX310 can help level the playing field by addressing both genetic and systemic obstacles that put certain communities at greater risk. This shift toward equitable care could transform not just individual lives, but entire communities impacted by heart disease.

The Long Road Ahead for CRISPR Therapies

While the results of CTX310 are exciting, CRISPR therapies like this come with a need for careful, long-term testing. The U.S. Food and Drug Administration advises long-term safety monitoring for up to 15 years for CRISPR-based studies. This extended follow-up is necessary because gene-editing treatments work directly on DNA, creating changes that could last a lifetime. Ensuring those changes are both safe and effective over the long term is critical.

So far, early trials of CTX310 have been reassuring. Only minor side effects like back pain and nausea have been reported, and these were resolved with medication. One participant experienced a temporary rise in liver enzymes, which returned to normal without needing treatment. While this is good news, researchers need to continue studying these treatments in larger, more diverse groups to fully understand their effects.

CRISPR technology is still new, and making it accessible to everyone won’t happen overnight. Developing these therapies for widespread use takes time, resources, and rigorous oversight. But the potential to replace years of pills or injections with a one-time infusion is a game-changer worth the wait. While safety and accessibility remain priorities, this groundbreaking technology offers a glimpse of what medicine could become in the near future.

The Future of Cardiovascular Health and Genetic Liberation

Imagine a future where managing cholesterol isn’t about remembering pills or scheduling injections but about a one-time solution that transforms your health from the inside out. That’s the vision behind genetic liberation therapy—a groundbreaking approach to cardiovascular health that aims to free people from the daily grind of chronic disease management. According to Cleveland Clinic cardiologist Luke Laffin, the aim is to move from daily pills or monthly injections to a one-time, safe, and durable infusion for patients with high cholesterol.

One of the most critical barriers in heart disease care today is treatment adherence. Many patients stop taking their medications within a year. The reasons vary—cost, side effects, or simply the difficulty of keeping up with long-term prescriptions. Genetic therapies like CTX310 aim to change that. By addressing cholesterol at the source—our DNA—these treatments have the potential to offer not just convenience but also long-term freedom from health burdens that weigh heavily on everyday life.

What makes this approach so transformative is the power to rewrite the genetic code for healing. Instead of merely treating symptoms, genetic editing tackles the root cause, bringing the possibility of a permanent solution**. This isn’t just about science—it’s about creating access, reducing health inequities, and empowering people to live fuller, healthier lives without the constant stress of managing chronic conditions.

Gene-editing therapies like this represent a new chapter in medicine: one that focuses on fairness, innovation, and liberation for all.

Community-Centered Medicine and Ubuntu Village

True healing goes beyond just treating symptoms—it’s about strengthening communities and ensuring everyone has access to the care they deserve. This is the philosophy behind **community-centered medicine** and the Ubuntu Village approach. Rooted in the belief that health is interconnected, Ubuntu emphasizes that when one person thrives, the whole community benefits.

For many, health inequities, like cholesterol disparities, are tied to systemic challenges such as unequal access to care or affordable treatments. Innovations like CTX310 can play a key role in addressing these gaps, but they must be integrated thoughtfully, keeping the needs of marginalized communities at the forefront. Community-centered medicine is vital. When science aligns with the needs of the community, it can better address disparities in health care.

As we step into the future of medicine, it’s essential to ensure these breakthroughs are not limited to a privileged few. By prioritizing equity and compassion, advancements like CRISPR-Cas9 gene editing and CTX310 can empower communities to overcome health challenges together. Health isn’t just personal; it’s collective, and building healthier communities starts with making innovative solutions accessible to everyone.

References

• American Heart Association. (2025, November 8). First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides. American Heart Association Newsroom. Retrieved from https://newsroom.heart.org/news/first-in-human-trial-of-crispr-gene-editing-therapy-safely-lowered-cholesterol-triglyceridesCRISPR Therapeutics. (2025, November 8). Positive Phase 1 clinical data for CTX310 demonstrating deep and durable ANGPTL3 editing, triglyceride and lipid lowering. CRISPR Therapeutics Investor Relations. Retrieved from https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-positive-phase-1-clinical-data
• Cleveland Clinic. (2025, November 8). First-in-human trial of CRISPR gene-editing therapy shown to lower cholesterol and triglycerides safely. Cleveland Clinic Newsroom. Retrieved from https://newsroom.clevelandclinic.org/2025/11/08/cleveland-clinic-first-in-human-trial-of-crispr-gene-editing-therapy-shown-to-safely-lower-cholesterol-and-triglycerides

---

Understanding the Tob Gene and Its Role in Depression

Every child deserves hope. Every family deserves support. Every community deserves light.
At Ubuntu Village, your generosity helps us uplift lives, strengthen families, and build a future rooted in compassion and unity.

If our mission speaks to your heart, please consider making a donation today.
Your support truly makes a difference. ❤🙏

Donate here:

🌟 PayPal: https://www.paypal.com/donate/?hosted_button_id=NZXHK2RX7STX4

🌟 GoFundMe: https://www.gofundme.com/f/ubuntu-lights-the-way-fund-the-flame

🌟 Classy: https://giving.classy.org/campaign/705577/donate

Get in touch or learn more:
https://ubuntuvillageusa.org/contact-us/